Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-1101 in Relapsed or Refractory Hematologic Malignancies
NCT02543879Phase 1Completed
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Sep 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT-1101 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Forma Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Dose Limiting Toxicities at 4 weeks and 1 more. Started Sep 2015; status: completed.
02
Drugs
FT-1101
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02543879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543879.